Use of these drugs as medications, though, promising, may be restricted for various reasons to a select few.
Kurt Rasmussen
Advertisement
Kurt Rasmussen is the chief science officer at Delix Therapeutics.
Articles by Kurt Rasmussen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
2
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
3
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
4
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
5
